Gossamer Bio’s (GOSS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Gossamer Bio (NASDAQ:GOSS) in a report released on Monday,Benzinga reports.

Separately, Weiss Ratings lowered shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th. Three analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $3.20.

Gossamer Bio Price Performance

Shares of GOSS stock opened at $0.20 on Monday. The company has a market cap of $46.80 million, a PE ratio of -0.25 and a beta of 2.04. Gossamer Bio has a 1 year low of $0.11 and a 1 year high of $3.87. The stock’s 50 day simple moving average is $0.18 and its two-hundred day simple moving average is $0.80.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Friday, May 15th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $16.95 million during the quarter, compared to analysts’ expectations of $4.67 million. Equities research analysts expect that Gossamer Bio will post -0.37 EPS for the current year.

Hedge Funds Weigh In On Gossamer Bio

Several hedge funds have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. lifted its position in shares of Gossamer Bio by 32.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 1,098,914 shares of the company’s stock worth $181,000 after purchasing an additional 270,195 shares during the last quarter. Bank of America Corp DE increased its stake in Gossamer Bio by 66.5% in the 1st quarter. Bank of America Corp DE now owns 3,173,725 shares of the company’s stock worth $1,041,000 after buying an additional 1,267,056 shares during the period. ADAR1 Capital Management LLC lifted its holdings in Gossamer Bio by 233.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 287,531 shares of the company’s stock valued at $94,000 after buying an additional 503,100 shares in the last quarter. Kalehua Capital Management LLC bought a new stake in Gossamer Bio during the 1st quarter valued at about $3,363,000. Finally, Renaissance Technologies LLC boosted its position in Gossamer Bio by 84.8% in the 1st quarter. Renaissance Technologies LLC now owns 1,217,868 shares of the company’s stock valued at $400,000 after buying an additional 558,980 shares during the period. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.